• OPEN AN ACCOUNT
Indian Indices
Nifty
19,674.25 -68.10
(-0.34%)
Sensex
65,904.23 -104.92
( -0.16%)
Bank Nifty
44,612.05 -11.80
( -0.03%)
Nifty IT
32,906.30 -13.65
( -0.04%)
Global Indices
Nasdaq
13,211.81 -12.18
(-0.09%)
Dow Jones
33,963.84 -106.58
(-0.31%)
Hang Seng
18,057.45 402.04
(2.28%)
Nikkei 225
32,402.41 -168.62
(-0.52%)
Forex
USD-INR
83.11 0.01
(0.01%)
EUR-INR
88.51 -0.32
(-0.36%)
GBP-INR
102.21 -0.61
(-0.59%)
JPY-INR
0.56 0.00
(0.01%)

EQUITY - MARKET SCREENER

Shricon Industries Ltd
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
508961
INE753D01010
27.9846774
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
5.1
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

sun pharmaceuticals industries ltd
Sun Pharma proposes to acquire Taro
May 27,2023
Sun Pharmaceuticals Industries on 26 May 2023 has issued a letter to the Board of Directors of Taro Pharmaceutical Industries, Israel (Taro) with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares in Taro, other than any shares already held by the Company or its affiliates (For a purchase price of $38 per ordinary share) (Proposed Transaction).

The Proposed Transaction to be consummated in the form of a reverse triangular merger under the Israeli Companies Law, 1999 (ICL) and practice. In this context, Purchaser shall form a wholly owned subsidiary (SPV), which shall enter into a merger agreement with Taro, with the SPV merging with and into Taro and Taro surviving the merger transaction. Consequently, Taro shall become a wholly owned subsidiary of Purchaser and be de-listed from NYSE.